{"@id":"https://bioecon.ru/technology/sarcopenia-myostatin-activin-therapeutics/","@type":"Technology","cluster":"therapeutics-platforms","formats":{"html":"https://en.bioecon.ru/technology/sarcopenia-myostatin-activin-therapeutics/","json":"https://en.bioecon.ru/api/v1/technology/sarcopenia-myostatin-activin-therapeutics/index.json"},"id":"sarcopenia-myostatin-activin-therapeutics","industries":["longevity"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/longevity/"],"suppliers":["https://bioecon.ru/companies/biohaven/","https://bioecon.ru/companies/hanmi-pharmaceutical/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/regeneron-pharmaceuticals/","https://bioecon.ru/companies/roche-holding/","https://bioecon.ru/companies/scholar-rock/","https://bioecon.ru/companies/bioage-labs/","https://bioecon.ru/companies/hlb-genex/","https://bioecon.ru/companies/isomorphic-labs/","https://bioecon.ru/companies/algalif/","https://bioecon.ru/companies/codexis/"]},"maturity":4,"name":"Sarcopenia and muscle-preservation therapeutics (myostatin, activin pathway)","regions":["us","eu"],"risk":"high","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-09","entity":"hanmipharm.com","kind":"web","urls":["https://www.hanmipharm.com/science/pipeline/focused/hm500197.hm"]},{"date":"2026-11-09","entity":"pmc.ncbi.nlm.nih.gov","kind":"research","urls":["https://pmc.ncbi.nlm.nih.gov/articles/PMC12146653/"]},{"date":"2026-11-09","entity":"academic.oup.com","kind":"research","urls":["https://academic.oup.com/edrv/article/43/2/329/6370269","https://academic.oup.com/biomedgerontology/article/78/Supplement_1/32/7026116"]},{"date":"2026-11-09","entity":"atm.amegroups.org","kind":"web","urls":["https://atm.amegroups.org/article/view/153082/html"]}],"stages":[{"n":1,"title":"Select the cohort"},{"n":2,"title":"Choose endpoints"},{"n":3,"title":"Agree outcomes"}],"summary":"Drugs that block negative regulators of muscle growth; the field is largely in phase 2 and many candidates have struggled to reach phase 3 because muscle gains have not reliably become functional gains.","url":"/technology/sarcopenia-myostatin-activin-therapeutics/","verified":"2026-11-09"}